Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DREAMS

Financiado

Drug REpurposing with Artificial intelligence for Muscular disorderS

According to World Health Organization, to date, fewer than 6% of rare diseases (RDs) have an approved treatment option. In the light of this observation, it appears crucial to develop disruptive approaches that allow to find trea... ver más

31/10/2028

CECS

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

CENTRE DETUDE DES CELLULES SOUCHES No se ha especificado una descripción o un objeto social para esta compañía.

Ver 9 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-10-08

HORIZON-HLTH-2022-DISEASE-06-04-two-stage: Development of new effective therap... ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or...

I+D

Cerrada hace 2 años

0% 100% 100%

9 Participantes

CECS

1.67M€ | Lider

INSERM

895.00K€ | Participante

ZABALA

400.00K€ | Participante

SAMSARA THERAPEUTICS LTD

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RED2018-102491-T APLICACIONES TERAPEUTICAS DE LA NEUROCIENCIA DE SISTEMAS EN... 20K€ Cerrado

PID2021-122659OB-I00 REPOSICIONAMIENTO DE FARMACOS BASADO EN DATOS MEDIANTE REDES... 97K€ Cerrado

PRE2021-100416 MEDICINA INTERCEPTIVA, DESCUBRIMIENTO DE DIANAS Y REUTILIZAC... 101K€ Cerrado

TIN2012-31377 ADQUISICION DE CONOCIMIENTO EN FARMACOPROTEOMICA MEDIANTE ME... 39K€ Cerrado

PRE2019-090912 CREACION Y ANALISIS DE REDES DE ENFERMEDADES (DISEASE NETWOR... 98K€ Cerrado

GenDrug Genetically anchored drug target discovery for neglected dis... 1M€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2023-10-08
Fecha Fin: 2028-10-31

Líder del proyecto

CENTRE DETUDE DES CELLULES SOUCHES No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 7M€

Descripción del proyecto According to World Health Organization, to date, fewer than 6% of rare diseases (RDs) have an approved treatment option. In the light of this observation, it appears crucial to develop disruptive approaches that allow to find treatments for multiple RDs. To achieve this goal, DREAMS will start from 5 rare neuromuscular disorders (NMD) that share common pathophysiological characteristics related to dysfunctions of autophagy and desmin disorganization. Using skeletal muscle cells derived from induced pluripotent stem cells (skMC-iPSC), DREAMS will i) identify shared biomarkers of the 5 diseases and ii) perform a high throughput drug screen on all 5 diseases. Through a first Artificial Intelligence (AI) based solution, the output of the drug screening will be used to find drug targets shared between the diseases. A second AI based solution will be used to find drug candidates (repurposable drugs and new molecular entities) for these shared drug targets. A third AI-based solution will be used to find additional diseases that could be treated through the shared drug targets, in order to extend the indications for the most promising drug candidates. Following their discoveries, the promising drug candidates will be tested for efficacy and safety in both iPSC and mouse models of the 5 NMDs and additional diseases. In parallel, DREAMS will design an adaptive clinical trial to prepare the final stages of drug development of these novel drug candidates with multiple indications. Together, these technological and conceptual innovations will allow the DREAMS consortium to i) develop therapies to treat multiple NMDs and related diseases, ii) to create a novel clinical design that generates a regulatory pathway for drugs that treat heterogeneous groups of patients suffering from RDs iii) to further the scientific understanding of commonalities in RDs, and iv) to create a reusable drug development platform to discover safe and effective treatments for RDs in general.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores